We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Appeals Court Invalidates The Medicines Co.’s Angiomax Patents
Appeals Court Invalidates The Medicines Co.’s Angiomax Patents
The Federal Circuit Court of Appeals has ruled that two of The Medicines Company’s patents for its anticlotting drug Angiomax are invalid — a win for Hospira, which is planning a generic version of the treatment.